Two TScan Directors Resign Simultaneously as Cash-Strapped Biotech Restructures

summarizeSummary

TScan Therapeutics disclosed that two directors, Garry Nicholson and Gabriela Gruia, M.D., resigned effective October 13, 2026, with the board immediately reshuffling committee assignments. The simultaneous departures land amid going-concern doubt, a 75% workforce cut and a paused Phase 3 trial.

check_boxKey Events · Executive and Board Changes · TCRX

• Two Directors Resign Same Day

  Garry Nicholson and Gabriela Gruia, M.D. resigned from the Board and all committees effective October 13, 2026; the filing states neither resignation resulted from a disagreement with the company.

• Committees Reshuffled

  Stephen Biggar and R. Keith Woods were appointed to the Nominating and Corporate Governance Committee, with Woods as chairperson; the NCG Committee is now Woods, Katina Dorton and Stephen Biggar, and the Audit Committee is Dorton, Barbara Klencke and Woods.

• Timing Follows Deep Distress

  The resignations come after previously disclosed going-concern doubt, the Amgen collaboration termination (over $500 million in potential milestones lost), a 75% workforce reduction and the paused Phase 3 ALLOHA-2 trial.

• Capital Runway Pressure

  As previously reported, cash was expected to last only into Q2 2027, leaving the company dependent on raising capital or restructuring.

auto_awesomeAnalysis · TCRX · Life Sciences

Two of TScan's directors, Garry Nicholson and Gabriela Gruia, M.D., left the board on the same day, October 13, 2026. The company says neither departure stemmed from a disagreement over operations, practices or policies, but the timing is hard to ignore: this comes roughly six weeks after TScan disclosed going-concern doubt, lost its Amgen collaboration worth over $500 million in potential milestones, cut 75% of its workforce and paused its Phase 3 ALLOHA-2 trial. Board members typically do not exit en masse when a company is on stable footing, so the resignations add to the governance uncertainty around a company that already needs to raise capital to survive past Q2 2027. The board moved quickly to reshuffle committee assignments, naming Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee, with Woods as chairperson, which keeps the committees staffed but does not replace the departed directors' seats.